Abbott rises after FDA approves Xience V stent - MSN MoneyCentral
NEW YORK (AP) - Shares of Abbott Laboratories rose Thursday after regulators approved its drug-coated Xience V stent for sale. The Food and Drug Administration approved the stent late Wednesday, and Abbott expects it to take between 25 percent and 30
Source: news.moneycentral.msn.comFDA Advisory Committee Recommends Cardiovascular Safety Studies for - Medscape News
July 3, 2008 — New diabetes drugs should be subjected to studies to rule out cardiovascular risk, the FDA 's Endocrinologic and Metabolic Drugs Advisory Committee decided at a meeting this week. But the specifics of what exactly those studies
Source: www.medscape.comFDA approves Boston Scientific stent - Minneapolis-St Paul Business Journal
More funding, new leadership bolster Sinexus [San Jose] Boston Sci sells investments for $140M [Mpls./St. Paul] Weaving a tale of two med techs in Rhode Island [Mass High Tech] Boston Scientific Corp. announced Wednesday that the U.S. Food and Drug
Source: twincities.bizjournals.com
Sector Snap: Diabetes drug developers - MSN MoneyCentral
Amylin Ord Shs ( AMLN ) Stock Quote , Chart , News , Add to Watchlist NEW YORK (AP) - Proposals for tougher heart-risk studies on new Type 2 diabetes drugs weighed heavy on shares of Amylin Pharmaceuticals Inc. and Novo Nordisk AS Thursday, since
Source: news.moneycentral.msn.comWyeth, Progenics bowel drug wins EU approval - Guardian Unlimited
NEW YORK, July 3 (Reuters) - Wyeth and Progenics Pharmaceuticals Inc won European approval for Relistor, a drug used to treat constipation that occurs with the use of opioid painkillers, like morphine, the companies said on Thursday. The drug will be
Source: www.guardian.co.ukWyeth, Progenics get European constipation drug OK - Forbes
Drug developers Wyeth and Progenics Pharmaceuticals Inc. said Thursday European regulators approved Relistor as a treatment for constipation related to pain drugs taken by terminally ill patients. The injectable drug relieves opioid-induced
Source: www.forbes.com
Radiology-centers chain is in default, FDA says - Baltimore Sun
A regional chain of radiology centers and its owner are in default on $1.1 million in fines for performing mammograms after one of its facilities lost its certification to perform the procedure because of equipment problems, according to documents
Source: www.baltimoresun.comUPDATE 1-Adolor: FDA lifts hold on bowel drug; GSK may exit deal - Reuters
July 3 (Reuters) - Adolor Corp (ADLR.O: Quote , Profile , Research , Stock Buzz ) said U. S. health regulators lifted a clinical hold on its drug Entereg, which is being developed to treat bowel dysfunction in patients on opioid therapy, but said
Source: www.reuters.comFDA lifts clinical hold on Adolor bowel drug - CNN Money
NEW YORK (Associated Press) - Adolor Corp. said Thursday the Food and Drug Administration has lifted its clinical hold on the company's Entereg drug in chronically constipated patients taking opioid pain drugs. The drug is being developed in
Source: money.cnn.comAbbott rises after FDA approves Xience V stent - MSN MoneyCentral
NEW YORK (AP) - Shares of Abbott Laboratories rose Thursday after regulators approved its drug-coated Xience V stent for sale. The Food and Drug Administration approved the stent late Wednesday, and Abbott expects it to take between 25 percent and 30
Source: news.moneycentral.msn.comAdolor gets FDA nod to resume Entereg testing - Philadelphia Inquirer
The Food and Drug Administration said Adolor Corp. could resume clinical testing of its drug Entereg to treat bowel discomfort commonly associated with use of opioid painkillers, the Exton company said today. Development had been halted in April 2007
Source: www.philly.com
